NasdaqGM - Delayed Quote • USD
Esperion Therapeutics, Inc. (ESPR)
At close: 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 6 |
| Avg. Estimate | 0.05 | -0.21 | -0.4 | 0.05 |
| Low Estimate | -0.31 | -0.25 | -1 | -0.67 |
| High Estimate | 0.46 | -0.14 | 0.09 | 1.49 |
| Year Ago EPS | -0.79 | -0.46 | -2.03 | -0.4 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 6 |
| Avg. Estimate | 84.51M | 42.53M | 265.13M | 391.03M |
| Low Estimate | 28.9M | 38M | 174M | 266.1M |
| High Estimate | 144.57M | 50.66M | 328.2M | 710.2M |
| Year Ago Sales | 24.33M | 25.79M | 116.33M | 265.13M |
| Sales Growth (year/est) | 247.40% | 64.90% | 127.90% | 47.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.65 | -0.61 | -0.43 | -0.48 |
| EPS Actual | -0.79 | -0.46 | -0.37 | -0.5 |
| Difference | -0.14 | 0.15 | 0.06 | -0.02 |
| Surprise % | -21.50% | 24.60% | 14.00% | -4.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.05 | -0.21 | -0.4 | 0.05 |
| 7 Days Ago | 0.05 | -0.21 | -0.4 | 0.05 |
| 30 Days Ago | 0.01 | -0.21 | -0.44 | 0.2 |
| 60 Days Ago | -0.04 | 0.1 | -0.28 | 0.51 |
| 90 Days Ago | -0.07 | 0.06 | -0.34 | 0.33 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ESPR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 106.30% | -- | -- | 1.50% |
| Next Qtr. | 54.30% | -- | -- | 11.40% |
| Current Year | 80.30% | -- | -- | 5.20% |
| Next Year | 112.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 16.90% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/25/2024 |
| Reiterates | Needham: Buy to Buy | 3/25/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
| Reiterates | Needham: Buy to Buy | 2/27/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
Related Tickers
DCPH Deciphera Pharmaceuticals, Inc.
14.62
-0.34%
EOLS Evolus, Inc.
11.50
-1.71%
AVDL Avadel Pharmaceuticals plc
17.66
-2.38%
DVAX Dynavax Technologies Corporation
11.42
-2.89%
AQST Aquestive Therapeutics, Inc.
3.9000
-8.88%
ELAN Elanco Animal Health Incorporated
13.31
-1.15%
ITCI Intra-Cellular Therapies, Inc.
73.12
-1.20%
SBFM Sunshine Biopharma, Inc.
0.9300
-23.14%
OPTN OptiNose, Inc.
0.9253
-4.38%
VTRS Viatris Inc.
11.55
+1.67%